From 94c5c2b7bb8ae28ee4c16b5c9c9ed9b6d89618b1 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 22 Mar 2026 04:30:01 +0000 Subject: [PATCH] pipeline: clean 3 stale queue duplicates Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...6-03-22-arise-state-of-clinical-ai-2026.md | 72 ------------------- ...th-canada-rejects-dr-reddys-semaglutide.md | 67 ----------------- ...evidence-sutter-health-epic-integration.md | 71 ------------------ 3 files changed, 210 deletions(-) delete mode 100644 inbox/queue/2026-03-22-arise-state-of-clinical-ai-2026.md delete mode 100644 inbox/queue/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md delete mode 100644 inbox/queue/2026-03-22-openevidence-sutter-health-epic-integration.md diff --git a/inbox/queue/2026-03-22-arise-state-of-clinical-ai-2026.md b/inbox/queue/2026-03-22-arise-state-of-clinical-ai-2026.md deleted file mode 100644 index 8547151b..00000000 --- a/inbox/queue/2026-03-22-arise-state-of-clinical-ai-2026.md +++ /dev/null @@ -1,72 +0,0 @@ ---- -type: source -title: "State of Clinical AI Report 2026 (ARISE Network, Stanford-Harvard)" -author: "ARISE Network — Peter Brodeur MD, Ethan Goh MD, Adam Rodman MD, Jonathan Chen MD PhD" -url: https://arise-ai.org/report -date: 2026-01-01 -domain: health -secondary_domains: [ai-alignment] -format: report -status: enrichment -priority: high -tags: [clinical-ai, state-of-ai, stanford, harvard, arise, openevidence, safety-paradox, outcomes-evidence, real-world-performance] -processed_by: vida -processed_date: 2026-03-22 -enrichments_applied: ["medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md"] -extraction_model: "anthropic/claude-sonnet-4.5" ---- - -## Content - -The State of Clinical AI (2026) was released in January 2026 by the ARISE network, a Stanford-Harvard research collaboration. The inaugural report synthesizes evidence on clinical AI performance in real-world settings vs. controlled benchmarks. - -**Key findings:** - -**Benchmark vs. real-world gap:** -- LLMs demonstrate strong performance on diagnostic benchmarks and structured clinical cases -- Real-world performance "breaks down when systems must manage uncertainty, incomplete information, or multi-step workflows" — which describes everyday clinical care -- "Real-world care remains uneven" as an evidence base - -**The "Safety Paradox" (novel framing):** -- Clinicians turn to "nimble, consumer-facing medical search engines" (specifically citing OpenEvidence) to check drug interactions and summarize patient histories, "often bypassing slow internal IT systems" -- This represents a **safety paradox**: clinicians prioritize speed over compliance because institutional AI tools are too slow for clinical workflows -- OE adoption is explicitly characterized as **shadow-IT workaround behavior** that has become normalized - -**Evaluation framework:** -- The report argues current evaluation focuses on "engagement rather than outcomes" -- Calls for "clearer evidence, stronger escalation pathways, and evaluation frameworks that focus on outcomes rather than engagement alone" - -**OpenEvidence specifically named** as a case study of consumer-facing medical AI being used to bypass institutional oversight. - -Additional coverage: Stanford Department of Medicine news release, BABL AI, Harvard Science Review ("Beyond the Hype: The First Real Audit of Clinical AI," February 2026), Stanford HAI. - -## Agent Notes -**Why this matters:** The ARISE report is the first systematic, peer-network-authored overview of clinical AI's real-world state. Its framing of OE as "shadow IT" is significant — it recharacterizes OE's rapid adoption not as a sign of clinical value, but as clinicians working around institutional barriers. This frames the OE-Sutter Epic integration as moving from "shadow IT" to "officially sanctioned shadow IT" — the speed that made OE attractive is now institutionally embedded without resolving the governance gap. - -**What surprised me:** The explicit naming of OpenEvidence as a case study in the safety paradox. This is the first time a Stanford-affiliated academic review has characterized OE adoption as a workaround behavior rather than evidence of clinical value. At $12B valuation and 30M+ consultations/month, this framing matters for how OE's safety profile is evaluated. - -**What I expected but didn't find:** Specific outcome data for any clinical AI tool. The report explicitly identifies this as the field's core gap — the absence of outcomes data is the finding, not an absence of coverage. - -**KB connections:** -- Directly extends Session 9 finding on the valuation-evidence asymmetry (OE at $12B, one retrospective 5-case study) -- The "safety paradox" framing provides vocabulary for why OE's governance gap is structural, not accidental -- Connects to the Sutter Health EHR integration (February 2026) — embedding OE in Epic formally addresses the speed problem while potentially entrenching the governance gap - -**Extraction hints:** Extract the "safety paradox" framing as a named mechanism: clinicians bypassing institutional AI governance to use consumer-facing tools because institutional tools are too slow. This is generalizable beyond OE. Secondary: extract the benchmark-vs-real-world gap finding as it applies to clinical AI at scale. - -**Context:** The ARISE network is the most credible academic voice on clinical AI evaluation practices. The report's release in January 2026 — coinciding with the NOHARM study findings — represents a coordinated moment of academic accountability for a rapidly scaling industry. The Harvard Science Review calling it "the first real audit" signals its significance in the field. - -## Curator Notes (structured handoff for extractor) -PRIMARY CONNECTION: "medical LLM benchmarks don't translate to clinical impact" (existing KB claim) -WHY ARCHIVED: Provides the first systematic framework for understanding clinical AI real-world performance gaps, introduces the "safety paradox" framing for consumer AI workaround behavior -EXTRACTION HINT: The "safety paradox" is a novel mechanism claim — extract it separately from the benchmark-gap finding. Both have evidence (OE adoption behavior, real-world performance breakdown) and are specific enough to be arguable. - - -## Key Facts -- ARISE Network is a Stanford-Harvard research collaboration -- State of Clinical AI Report 2026 was released in January 2026 -- Report authors: Peter Brodeur MD, Ethan Goh MD, Adam Rodman MD, Jonathan Chen MD PhD -- Report explicitly names OpenEvidence as case study of consumer-facing medical AI -- Report calls for 'evaluation frameworks that focus on outcomes rather than engagement alone' -- Harvard Science Review called the report 'Beyond the Hype: The First Real Audit of Clinical AI' in February 2026 -- Report received coverage from Stanford Department of Medicine, BABL AI, Harvard Science Review, and Stanford HAI diff --git a/inbox/queue/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md b/inbox/queue/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md deleted file mode 100644 index 465b137a..00000000 --- a/inbox/queue/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md +++ /dev/null @@ -1,67 +0,0 @@ ---- -type: source -title: "Health Canada Rejects Dr. Reddy's Generic Semaglutide Application — Canada Launch Delayed to 2027 at Earliest" -author: "Business Standard / The Globe and Mail" -url: https://www.business-standard.com/companies/news/dr-reddys-labs-semaglutide-generic-canada-approval-delay-125103001103_1.html -date: 2025-10-30 -domain: health -secondary_domains: [] -format: news article -status: enrichment -priority: high -tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory, patent-cliff, obeda] -processed_by: vida -processed_date: 2026-03-22 -enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] -extraction_model: "anthropic/claude-sonnet-4.5" ---- - -## Content - -**Business Standard (October 2025):** Dr. Reddy's timeline to launch generic injectable semaglutide in Canada was set to be disrupted after the firm received a non-compliance notice (NoN) from Canada's Pharmaceutical Drugs Directorate. The notice could delay the launch by at least 8-12 months. - -**The Globe and Mail (subsequent coverage):** Health Canada rejected Dr. Reddy's Laboratories' application to make generic semaglutide — a setback for what was poised to be one of the first generic competitors to Ozempic to hit the market in 2026. - -**Company response:** Dr. Reddy's stated it is "in constant touch with Canadian regulators" and has "sent replies to their queries." The Canada launch is "on pause." - -**India launch confirmed:** Separately, Dr. Reddy's launched "Obeda" (generic semaglutide for Type 2 diabetes) in India — this is confirmed from the March 21, 2026 India generic market launch (Session 9 findings). - -**Context:** -- Canada's semaglutide patents expired January 2026 -- Dr. Reddy's was projecting May 2026 Canada launch in its 87-country rollout plan -- Multiple legal/patent complications in Canada (Pearce IP analysis, patentlawyermagazine.com coverage on "semaglutide saga" in Canada) -- Timeline: if re-submitted immediately after rejection, 8-12 months for new review = June-October 2026 re-submission → 2027 at earliest for approval - -**Session 9 error:** The March 21, 2026 research session projected Dr. Reddy's Canada May 2026 launch as a near-term confirmed data point. This was incorrect — the Health Canada rejection means no Canada data in 2026. - -## Agent Notes -**Why this matters:** Canada was the single clearest near-term data point for what generic semaglutide looks like in a major, high-income market with a functioning generic drug approval system. India's Day-1 pricing ($15-55/month) established the floor for low-income markets. Canada would have established the floor for high-income markets with similar health infrastructure to the US. That data point is now delayed to 2027 at earliest. - -**What surprised me:** The Health Canada rejection was not anticipated in any of the bullish GLP-1 generic coverage. The India launch coverage (Sessions 8-9) projected smooth Canada entry given the January 2026 patent expiration. The regulatory rejection is a material setback to the "generic access within 12 months of patent expiry" narrative. - -**What I expected but didn't find:** An explanation of what specifically was non-compliant in Dr. Reddy's submission. The Business Standard coverage doesn't specify the technical grounds — whether it's manufacturing quality, bioequivalence data, device design, or another issue. This matters because different rejection reasons have different remediation timelines. - -**KB connections:** -- Directly updates Session 9 finding (Canada May 2026 launch was a key thread — now confirmed delayed) -- Recalibrates the GLP-1 global generic rollout timeline: India confirmed, Canada 2027+, Brazil/Turkey TBD -- The "US gray market importation" thread (Sessions 8-9): Canada was expected to be the primary source of legal/gray market US importation. That channel is now delayed. -- The GLP-1 KB claim update ("inflationary through 2035" → split by market): the Canada delay means international price data for high-income markets is further away than projected - -**Extraction hints:** The primary claim is a timeline correction: Canada generic semaglutide launch is 2027 at earliest (not 2026 as the global rollout narrative projected). The secondary claim is about regulatory friction as a barrier to generic market entry that the India-first narrative didn't adequately account for. - -**Context:** This source corrects a material error in Session 9. The May 2026 Canada launch was listed as a key active thread and near-term data point. That thread is now effectively closed until 2027. The India price data remains the only live data point for post-patent generic semaglutide markets. - -## Curator Notes (structured handoff for extractor) -PRIMARY CONNECTION: GLP-1 receptor agonists claim ("inflationary through 2035") and the Session 21 claim candidate about Dr. Reddy's 87-country rollout -WHY ARCHIVED: Corrects the Session 9 projection; establishes regulatory friction as an underappreciated barrier to generic GLP-1 global rollout -EXTRACTION HINT: The claim candidate from Session 9 about Dr. Reddy's clearing 87 countries for 2026 rollout needs updating — Canada is NOT in the 2026 timeline. The extractor should flag this as a correction to Session 9's claim candidate 2. - - -## Key Facts -- Dr. Reddy's received a non-compliance notice (NoN) from Canada's Pharmaceutical Drugs Directorate in October 2025 -- Canada's semaglutide patents expired January 2026 -- Dr. Reddy's projected May 2026 Canada launch in its 87-country rollout plan -- Regulatory re-submission and review timeline: 8-12 months minimum -- Dr. Reddy's stated it is 'in constant touch with Canadian regulators' and has 'sent replies to their queries' -- The Canada launch is 'on pause' per company statement -- India launch of Obeda (generic semaglutide) confirmed March 21, 2026 diff --git a/inbox/queue/2026-03-22-openevidence-sutter-health-epic-integration.md b/inbox/queue/2026-03-22-openevidence-sutter-health-epic-integration.md deleted file mode 100644 index 2f39b659..00000000 --- a/inbox/queue/2026-03-22-openevidence-sutter-health-epic-integration.md +++ /dev/null @@ -1,71 +0,0 @@ ---- -type: source -title: "OpenEvidence Embeds in Epic EHR at Sutter Health (February 2026)" -author: "BusinessWire / OpenEvidence / Sutter Health" -url: https://www.businesswire.com/news/home/20260211318919/en/Sutter-Health-Collaborates-with-OpenEvidence-to-Bring-Evidence-Based-AI-Powered-Insights-into-Physician-Workflows -date: 2026-02-11 -domain: health -secondary_domains: [ai-alignment] -format: press release -status: enrichment -priority: medium -tags: [openevidence, sutter-health, epic-ehr, clinical-ai, ehr-integration, workflow-ai, automation-bias, california] -processed_by: vida -processed_date: 2026-03-22 -enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md"] -extraction_model: "anthropic/claude-sonnet-4.5" ---- - -## Content - -Announced February 11, 2026: Sutter Health (one of California's largest health systems, ~12,000+ affiliated physicians) has entered a collaboration with OpenEvidence to embed AI-powered clinical decision support within Epic EHR workflows. - -**Key details:** -- OE will be integrated within Epic's electronic health record system at Sutter Health -- Enables natural-language search for guidelines, peer-reviewed studies, and clinical evidence within the EHR -- Physicians can access OE during clinical workflow without opening a separate application -- Stated goal: "advance healthcare sustainability and medical AI safety" -- Sutter Health: 30 hospitals, 900+ care centers, ~12,000 affiliated physicians in California - -**Context from other sources:** -- BusinessWire announcement (February 11, 2026); Healthcare IT News; HLTH platform coverage -- Sutter Health is described as having "high standards for quality, safety and patient-centered care" -- No mention of prospective outcomes study or safety evaluation pre-deployment -- The partnership announcement coincides with OE being cited in the ARISE State of Clinical AI 2026 as a "consumer-facing" tool used to bypass institutional IT - -**Previously:** OE was primarily used as a standalone app — physicians opened it separately from their EHR. The Sutter integration makes OE a native in-workflow tool. - -## Agent Notes -**Why this matters:** This is a structural shift in how OE's safety risk profile operates. A tool used as a voluntary external lookup has different automation bias dynamics than a tool embedded in the clinical workflow. Research on in-context vs. external AI consistently shows in-context suggestions generate higher adherence. The Sutter integration essentially institutionalizes the "safety paradox" that ARISE identified — instead of physicians bypassing institutional governance to use OE, Sutter's institutional governance IS OE. - -**What surprised me:** The absence of any mention of pre-deployment safety evaluation. Given that: -- The NOHARM study found 12-22% severe clinical errors in top LLMs (published January 2026) -- The Nature Medicine bias study documented systematic demographic bias across all models (2025) -- OE has zero prospective clinical outcomes evidence -...it is notable that a major health system is embedding OE in primary clinical workflows without mentioning a formal safety evaluation. This is the scale-safety asymmetry at its most acute. - -**What I expected but didn't find:** Any mention of: how OE's model was selected, what safety benchmarks were reviewed, whether OE was evaluated against NOHARM or similar frameworks before deployment, or what clinical governance oversight Sutter has put in place for in-EHR AI. - -**KB connections:** -- Extends Session 9 finding on OE scale-safety asymmetry (now at health-system EHR level) -- Connects to Session 8 (Catalini verification bandwidth) — in-EHR suggestions at physician workflow speed make verification even harder -- ARISE "safety paradox" framing applies directly: this integration institutionalizes the workaround -- If OE has the sociodemographic biases documented in the Nature Medicine study, those biases are now embedded in Sutter's clinical workflows - -**Extraction hints:** The primary claim is structural: EHR embedding of clinical AI with zero prospective outcomes evidence creates a different (higher) automation bias risk profile than standalone app use. The absence of safety evaluation documentation before deployment is itself a finding about governance gaps. - -**Context:** Sutter Health is a major California health system that serves approximately 3.3 million patients annually. Its physician count (~12,000 affiliated) means the OE-Epic integration could affect millions of patient encounters annually. This is not a pilot — it's a full health-system deployment. - -## Curator Notes (structured handoff for extractor) -PRIMARY CONNECTION: Session 9 finding on OpenEvidence scale (30M+ monthly consultations, valuation-evidence asymmetry) -WHY ARCHIVED: First major EHR integration of OE — changes the automation bias risk profile from standalone app to in-workflow embedded tool; no safety evaluation mentioned pre-deployment -EXTRACTION HINT: Focus on the governance gap: EHR embedding without prospective safety validation. This is a structural claim about how health system procurement decisions interact with clinical AI safety evidence requirements. - - -## Key Facts -- Sutter Health operates 30 hospitals and 900+ care centers in California -- Sutter Health has approximately 12,000 affiliated physicians -- Sutter Health serves approximately 3.3 million patients annually -- OpenEvidence-Sutter Health integration announced February 11, 2026 -- Integration enables natural-language search for guidelines, peer-reviewed studies, and clinical evidence within Epic EHR -- Stated goal includes 'advance healthcare sustainability and medical AI safety'